Chronic effects of different THC:CBD ratios on executive function and emotional processing in people with multiple sclerosis

项目摘要 大约70%的多发性硬化症(PWMS)患者会自行用大麻治疗他们的症状。Δ-9- 四氢大麻酚(THC)和大麻二酚(CBD)是含量最丰富的大麻成分。THC 表现出精神活性，可能导致急性精神病，并影响执行功能。CBD不是 像THC一样的精神活性，已经被证明对情感有益(即，缓解焦虑)，抗炎， 并具有神经保护作用。关键的是，THC和CBD的数量(即比率)存在巨大差异 商业上可以买到的。因此，不同品系大麻的THC/CBD的比例可能具有关键作用。 对PWMS的执行功能和情绪处理(即恐惧、焦虑)的影响。目前，有一个差距 了解不同比例的THC：CBD对大脑活动、执行功能、 和PWMS中的情绪处理。 此应用程序的目标是进行一项独特的观察性、横断面研究，该研究采用真实世界 目前爱荷华州居民可获得不同THC：CBD比率的大麻产品。我们会调查的 精神分裂症患者在执行功能、情绪加工和脑活动方面的差异 大麻的不同THC：CBD比率至少6个月[高CBD组(CBD&GT；THC)；1：1组(THC= 高THC组(THC和GT；CBD)；非使用者组(不吸食大麻)]。执行功能和情感 处理过程将通过有效的精神和神经心理测量进行评估。正电子发射 使用[18F]-氟代脱氧葡萄糖(FDG)的断层扫描(PET)将被用作衡量大脑活动的指标。 我们的中心假设是，高THC组的执行功能和情绪会更差 与高CBD、1：1和非用户组相比的处理，以及高CBD组将具有 与高THC组、1：1组和非使用者组相比，情绪处理更好。这些假设是 根据之前的研究和我们自己的初步数据制定的。 这项关于目前正在使用大麻的PWMS的研究很好地告诉我们 了解不同THC：CBD比率的影响和未来纵向研究的重点途径 (R01)。

Project Summary Approximately 70% of people with multiple sclerosis (PwMS) self-medicate their symptoms with cannabis. Δ-9- tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most abundant cannabis components. THC exhibits psychoactive effects, may induce acute psychosis, and impacts executive function. CBD is not psychoactive like THC and has been shown to be emotionally beneficial (i.e., anxiolytic), anti-inflammatory, and neuroprotective. Critically, there is a vast diversity in the amounts (i.e., ratios) of THC and CBD commercially available. Therefore, the ratio of THC: CBD of various strains of cannabis may have a pivotal impact on executive function and emotional processing (i.e., fear, anxiety) in PwMS. Currently, there is a gap of understanding surrounding the effects of different ratios of THC:CBD on brain activity, executive function, and emotional processing in PwMS. The goal of this application is to conduct a unique observational, cross-sectional study that employs real-world cannabis products of varying THC:CBD ratios currently available to Iowa residents. We will investigate differences in executive function, emotional processing, and brain activity in PwMS who have been using different THC:CBD ratios of cannabis for at least 6 months [High CBD group (CBD >THC); 1:1 group (THC = CBD); High THC group (THC > CBD); Non-Users group (no cannabis)]. Executive function and emotional processing will be assessed with valid psychiatric and neuropsychological measures. Positron Emission Tomography (PET) with [18F]-Fluorodeoxyglucose (FDG) will be used as a measure of brain activity. Our central hypothesis is that the High THC group will have worse executive function and emotional processing compared to the High CBD, 1:1, and Non-Users groups, and that the High CBD group will have better emotional processing compared to the High THC, 1:1, and Non-Users groups. These hypotheses were formulated based on previous studies and our own preliminary data. This research on PwMS who are currently using cannabis is well-positioned to critically inform our understanding of the effects of different THC:CBD ratios and highlight avenues for future longitudinal studies (R01).